MIRA Pharmaceuticals held its 2024 Annual Meeting on September 12, 2024, with 63.72% of outstanding shares represented. Stockholders elected five directors: Erez Aminov, Michael Jerman, Matthew Del Giudice, M.D., Denil Nanji Shekhat, M.D., and Edward MacPherson, to serve until the next Annual Meeting.The appointment of Cherry Bekaert LLP as the independent registered public accounting firm for FY2024 was ratified. Shareholders also approved amendments to the 2022 Omnibus Incentive Plan to increase available shares. The proposal to adjourn the meeting if necessary was withdrawn as other proposals passed.Voting results showed strong support for all proposals, with director nominees receiving over 6.6 million votes each, and the accounting firm appointment garnering over 9.4 million votes in favor.

MIRA Pharmaceuticals held its 2024 Annual Meeting on September 12, 2024, with 63.72% of outstanding shares represented. Stockholders elected five directors: Erez Aminov, Michael Jerman, Matthew Del Giudice, M.D., Denil Nanji Shekhat, M.D., and Edward MacPherson, to serve until the next Annual Meeting.The appointment of Cherry Bekaert LLP as the independent registered public accounting firm for FY2024 was ratified. Shareholders also approved amendments to the 2022 Omnibus Incentive Plan to increase available shares. The proposal to adjourn the meeting if necessary was withdrawn as other proposals passed.Voting results showed strong support for all proposals, with director nominees receiving over 6.6 million votes each, and the accounting firm appointment garnering over 9.4 million votes in favor.